Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Down 26.0% in November

Traws Pharma, Inc. (NASDAQ:TRAW) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 7,700 shares, a decline of 26.0% from the November 15th total of 10,400 shares. Based on an average daily volume of 11,600 shares, the short-interest ratio is currently 0.7 days. Approximately 0.3% of the company’s stock are short sold.

Traws Pharma Price Performance

TRAW stock traded down $0.22 during midday trading on Friday, reaching $4.62. The company had a trading volume of 3,528 shares, compared to its average volume of 5,944. The company’s 50 day moving average price is $4.96. The stock has a market capitalization of $14.00 million, a P/E ratio of -0.03 and a beta of 1.46. Traws Pharma has a 1 year low of $4.06 and a 1 year high of $27.50.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.